Centanafadine

Apr 26, 2026 - 18:22
0 0
Centanafadine

Added a 3D structure and captions for both 2D and 3D structures.

← Previous revision Revision as of 12:50, 26 April 2026
Line 7: Line 7:
| width = 180
| width = 180


| caption = Molecular structure of centanafadine
| image2 = Centanafadine 3D.png
| tradename =
| routes_of_administration =
| tradename =
| routes_of_administration =
| legal_US = Investigational New Drug
| legal_US = Investigational New Drug
| legal_status =
| legal_status =

| CAS_number = 924012-43-1
| CAS_number = 924012-43-1
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = D2A6T4UH9C
| UNII = D2A6T4UH9C
| ATC_suffix =
| ATC_suffix =
| PubChem = 16095349
| PubChem = 16095349
| ChemSpiderID = 17253639
| ChemSpiderID = 17253639
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D10697
| KEGG = D10697


| C = 15
| C=15 | H=15 | N=1
| H = 15
| N = 1
| smiles = C1=C(C=CC2=CC=CC=C12)[C@@]34C[C@@H]3CNC4
| smiles = C1=C(C=CC2=CC=CC=C12)[C@@]34C[C@@H]3CNC4
| StdInChI = 1S/C15H15N/c1-2-4-12-7-13(6-5-11(12)3-1)15-8-14(15)9-16-10-15/h1-7,14,16H,8-10H2/t14-,15+/m1/s1
| StdInChI = 1S/C15H15N/c1-2-4-12-7-13(6-5-11(12)3-1)15-8-14(15)9-16-10-15/h1-7,14,16H,8-10H2/t14-,15+/m1/s1
| StdInChIKey = HKHCSWPSUSWGLI-CABCVRRESA-N
| StdInChIKey = HKHCSWPSUSWGLI-CABCVRRESA-N
| caption2 = 3D representation of a centanafadine molecule
}}
}}


'''Centanafadine''' ([[International Nonproprietary Name|INN]]; former developmental code name '''EB-1020''') is a [[serotonin-norepinephrine-dopamine reuptake inhibitor]] (SNDRI) that began its [[drug development|development]] with [[Euthymics Bioscience]] after they acquired [[DOV Pharmaceutical]]. It was developed as a treatment for [[attention-deficit hyperactivity disorder]] (ADHD) and inhibits the [[reuptake]] of [[norepinephrine]], [[dopamine]], and [[serotonin]] with an IC50 ratio of 1:6:14, respectively.{{cite web | url=http://www.neurovance.com/science/ | title=3-Neurotransmitters, 1-Molecule: Optimized Ratios | publisher=Neurovance}}{{cite web | url=http://euthymics.com/wp-content/uploads/2012/10/White-Paper-EB1020-092612.pdf | title=EB-1020, a Non-Stimulant Norepinephrine and Dopamine - Preferring Reuptake Inhibitor for the Treatment of Adult ADHD | publisher=Neurovance | access-date=2015-11-14 | archive-date=2015-11-17 | archive-url=https://web.archive.org/web/20151117023856/http://euthymics.com/wp-content/uploads/2012/10/White-Paper-EB1020-092612.pdf | url-status=dead }}{{cite journal | vauthors = Bymaster FP, Golembiowska K, Kowalska M, Choi YK, Tarazi FI | title = Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: implications for treatment of attention-deficit hyperactivity disorder | journal = Synapse | volume = 66 | issue = 6 | pages = 522–32 | date = June 2012 | pmid = 22298359 | doi = 10.1002/syn.21538 | s2cid = 38850652 }} In 2011, [[Euthymics Bioscience]] spun off its development of centanafadine to a new company called Neurovance.{{cite web|title=Euthymics|url=http://euthymics.com/|website=Ethismos Research Inc.|access-date=14 January 2018|ref=euthymics}}{{cite news|title=EUTHYMICS BIOSCIENCE, INC. PRESENTS DATA THAT SUPPORT ADVANCING EB-1020 INTO CLINICAL TRIALS FOR ADULT ADHD|url=http://www.neurovance.com/wp-content/uploads/2014/04/Neurovance_120711.pdf|access-date=14 January 2018|publisher=Neurovance|date=December 7, 2011}} In March 2017, Otsuka Pharmaceutical acquired Neurovance and the rights to centanafadine.{{cite web|title=Otsuka Pharmaceutical to Acquire Neurovance, Inc.|url=https://www.otsuka-us.com/discover/articles-1000|publisher=Otsuka|access-date=14 January 2018}} {{As of|2025|November|24}}, Otsuka's pipeline indicates it is in [[Phases of clinical research|phase II and III clinical trials]] for a number of different applications to medical conditions.{{cite web | title=Otsuka Pharmaceutical Submits New Drug Application to U.S. FDA for Centanafadine for the Treatment of ADHD in Children, Adolescents, and Adults | website=Otsuka US | date=25 November 2025 | url=https://www.otsuka-us.com/news/otsuka-pharmaceutical-submits-new-drug-application-us-fda-centanafadine-treatment-adhd | access-date=15 February 2026}}{{cite web|title=Otsuka U.S. Research & Development Programs|url=https://www.otsuka-us.com/media/images/AR-5-11-2017-OTS-US-Pipeline-Graphic-v02_959.jpg|website=Otsuka U.S.|publisher=Otsuka|access-date=14 January 2018}}{{Dead link|date=November 2019 |bot=InternetArchiveBot |fix-attempted=yes }}{{Cite web |last=Otsuka Pharmaceutical Development & Commercialization, Inc. |date=2021-09-17 |title=A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group Trial Evaluating the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder |url=https://clinicaltrials.gov/ct2/show/results/NCT03605680}}{{Cite web |last=Gunduz-Bruce |first=Handan |date=2018-09-26 |title=SAGE-217 in major depressive disorder: a multicenter, randomized, double-blind, Phase 2 placebo-controlled trial |url=http://dx.doi.org/10.26226/morressier.5b68175eb56e9b005965c44b |access-date=2023-06-26 |doi=10.26226/morressier.5b68175eb56e9b005965c44b |s2cid=266120058 }}
'''Centanafadine''' ([[International Nonproprietary Name|INN]]; former developmental code name '''EB-1020''') is a [[serotonin-norepinephrine-dopamine reuptake inhibitor]] (SNDRI) that began its [[drug development|development]] with [[Euthymics Bioscience]] after they acquired [[DOV Pharmaceutical]]. It was developed as a treatment for [[attention-deficit hyperactivity disorder]] (ADHD) and inhibits the [[reuptake]] of [[norepinephrine]], [[dopamine]], and [[serotonin]] with an IC50 ratio of 1:6:14, respectively.{{cite web | url=http://www.neurovance.com/science/ | title=3-Neurotransmitters, 1-Molecule: Optimized Ratios | publisher=Neurovance}}{{cite web | url=http://euthymics.com/wp-content/uploads/2012/10/White-Paper-EB1020-092612.pdf | title=EB-1020, a Non-Stimulant Norepinephrine and Dopamine - Preferring Reuptake Inhibitor for the Treatment of Adult ADHD | publisher=Neurovance | access-date=2015-11-14 | archive-date=2015-11-17 | archive-url=https://web.archive.org/web/20151117023856/http://euthymics.com/wp-content/uploads/2012/10/White-Paper-EB1020-092612.pdf | url-status=dead }}{{cite journal | vauthors = Bymaster FP, Golembiowska K, Kowalska M, Choi YK, Tarazi FI | title = Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: implications for treatment of attention-deficit hyperactivity disorder | journal = Synapse | volume = 66 | issue = 6 | pages = 522–32 | date = June 2012 | pmid = 22298359 | doi = 10.1002/syn.21538 | s2cid = 38850652 }} In 2011, Euthymics Bioscience spun off its development of centanafadine to a new company called Neurovance.{{cite web|title=Euthymics|url=http://euthymics.com/|website=Ethismos Research Inc.|access-date=14 January 2018|ref=euthymics}}{{cite news|title=EUTHYMICS BIOSCIENCE, INC. PRESENTS DATA THAT SUPPORT ADVANCING EB-1020 INTO CLINICAL TRIALS FOR ADULT ADHD|url=http://www.neurovance.com/wp-content/uploads/2014/04/Neurovance_120711.pdf|access-date=14 January 2018|publisher=Neurovance|date=December 7, 2011}} In March 2017, Otsuka Pharmaceutical acquired Neurovance and the rights to centanafadine.{{cite web|title=Otsuka Pharmaceutical to Acquire Neurovance, Inc.|url=https://www.otsuka-us.com/discover/articles-1000|publisher=Otsuka|access-date=14 January 2018}} {{As of|2025|November|24}}, Otsuka's pipeline indicates it is in [[Phases of clinical research|phase II and III clinical trials]] for a number of different applications to medical conditions.{{cite web | title=Otsuka Pharmaceutical Submits New Drug Application to U.S. FDA for Centanafadine for the Treatment of ADHD in Children, Adolescents, and Adults | website=Otsuka US | date=25 November 2025 | url=https://www.otsuka-us.com/news/otsuka-pharmaceutical-submits-new-drug-application-us-fda-centanafadine-treatment-adhd | access-date=15 February 2026}}{{cite web|title=Otsuka U.S. Research & Development Programs|url=https://www.otsuka-us.com/media/images/AR-5-11-2017-OTS-US-Pipeline-Graphic-v02_959.jpg|website=Otsuka U.S.|publisher=Otsuka|access-date=14 January 2018}}{{Dead link|date=November 2019 |bot=InternetArchiveBot |fix-attempted=yes }}{{Cite web |last=Otsuka Pharmaceutical Development & Commercialization, Inc. |date=2021-09-17 |title=A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group Trial Evaluating the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder |url=https://clinicaltrials.gov/ct2/show/results/NCT03605680}}{{Cite web |last=Gunduz-Bruce |first=Handan |date=2018-09-26 |title=SAGE-217 in major depressive disorder: a multicenter, randomized, double-blind, Phase 2 placebo-controlled trial |url=http://dx.doi.org/10.26226/morressier.5b68175eb56e9b005965c44b |access-date=2023-06-26 |doi=10.26226/morressier.5b68175eb56e9b005965c44b |s2cid=266120058 }}


{| class="wikitable floatleft"
{| class="wikitable floatleft"
Read More